Deciphering metabolic dysfunction-associated steatotic liver disease: insights from predictive modeling and clustering analysis

被引:7
|
作者
Mori, Kazuma [1 ,8 ]
Akiyama, Yukinori [2 ]
Tanaka, Marenao [1 ]
Sato, Tatsuya [1 ,3 ]
Endo, Keisuke [1 ]
Hosaka, Itaru [4 ]
Hanawa, Nagisa [5 ]
Sakamoto, Naoya [6 ,7 ]
Furuhashi, Masato [1 ]
机构
[1] Sapporo Med Univ, Sch Med, Dept Cardiovasc Renal & Metab Med, S-1,W-16,Chuo Ku, Sapporo 0608543, Japan
[2] Sapporo Med Univ, Sch Med, Dept Neurosurg, Sapporo, Japan
[3] Sapporo Med Univ, Sch Med, Dept Cellular Physiol & Signal Transduct, Sapporo, Japan
[4] Sapporo Med Univ, Sch Med, Dept Cardiovasc Surg, Sapporo, Japan
[5] Keijinkai Maruyama Clin, Dept Hlth Checkup & Promot, Sapporo, Japan
[6] Hokkaido Univ, Fac Med, Dept Gastroenterol & Hepatol, Sapporo, Japan
[7] Grad Sch Med, Sapporo, Japan
[8] Natl Def Med Coll, Dept Immunol & Microbiol, Tokorozawa, Japan
基金
日本学术振兴会;
关键词
clustering; machine learning; metabolic dysfunction-associated fatty liver disease (MAFLD); metabolic dysfunction-associated steatotic liver disease (MASLD); nonalcoholic fatty liver disease (NAFLD); CLINICAL-PRACTICE GUIDELINES; DELPHI CONSENSUS STATEMENT; ALCOHOL-CONSUMPTION; HEPATITIS-C; INDEX; RISK; INDIVIDUALS; PREVALENCE; MECHANISMS; FACTORIAL;
D O I
10.1111/jgh.16552
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and AimNew nomenclature of steatotic liver disease (SLD) including metabolic dysfunction-associated SLD (MASLD), MASLD and increased alcohol intake (MetALD), and alcohol-associated liver disease (ALD) has recently been proposed. We investigated clustering analyses to decipher the complex landscape of SLD pathologies including the former nomenclature of nonalcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated fatty liver disease (MAFLD).MethodsJapanese individuals who received annual health checkups including abdominal ultrasonography (n = 15 788, men/women: 10 250/5538, mean age: 49 years) were recruited.ResultsThe numbers of individuals with SLD, MASLD, MetALD, ALD, NAFLD, and MAFLD were 5603 (35.5%), 4227 (26.8%), 795 (5.0%), 324 (2.1%), 3982 (25.8%), and 4946 (31.3%), respectively. Clustering analyses using t-distributed stochastic neighbor embedding and K-means to visually represent interconnections in SLDs uncovered five cluster formations. MASLD and NAFLD mainly shared three clusters including (i) low alcohol intake with relatively low-grade obesity; (ii) obesity with dyslipidemia; and (iii) dysfunction of glucose metabolism. Both MetALD and ALD displayed one distinct cluster intertwined with alcohol consumption. MAFLD widely shared all of the five clusters. In machine learning-based analyses using algorithms of random forest and extreme gradient boosting and receiver operating characteristic curve analyses, fatty liver index (FLI), calculated by body mass index, waist circumference, and levels of gamma-glutamyl transferase and triglycerides, was selected as a useful feature for SLDs.ConclusionsThe new nomenclature of SLDs is useful for obtaining a better understanding of liver pathologies and for providing valuable insights into predictive factors and the dynamic interplay of diseases. FLI may be a noninvasive predictive marker for detection of SLDs. 1 image
引用
收藏
页码:1382 / 1393
页数:12
相关论文
共 50 条
  • [41] Severe obesity is associated with worse outcomes than lean metabolic dysfunction-associated steatotic liver disease
    Behari, Jaideep
    Wang, Renwei
    Luu, Hung N.
    Mckenzie, David
    Molinari, Michele
    Yuan, Jian-Min
    HEPATOLOGY COMMUNICATIONS, 2024, 8 (07)
  • [42] Are we ready for genetic testing in metabolic dysfunction-associated steatotic liver disease?
    Tulone, Adele
    Pennisi, Grazia
    Ciccioli, Carlo
    Infantino, Giuseppe
    La Mantia, Claudia
    Cannella, Roberto
    Mercurio, Francesco
    Petta, Salvatore
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2024, 12 (05) : 638 - 648
  • [43] Ferroptosis is a targetable detrimental factor in metabolic dysfunction-associated steatotic liver disease
    Peleman, Cedric
    Hellemans, Stig
    Veeckmans, Geraldine
    Arras, Wout
    Zheng, Hao
    Koeken, Ine
    Van San, Emily
    Hassannia, Behrouz
    Walravens, Magali
    Kayirangwa, Edissa
    Beyene, Nateneal Tamerat
    Van Herck, Mikhail Alfons
    De Vos, Winnok Harald
    Pintelon, Isabel
    van Nassauw, Luc
    Oosterlinck, Baptiste
    Smet, Annemieke
    Vits, Lieve
    Dirinck, Eveline
    Verrijken, An
    De Man, Joris
    Van Eyck, Annelies
    Kwanten, Wilhelmus Josephus
    Vonghia, Luisa
    Driessen, Ann
    Augustyns, Koen
    Toyokuni, Shinya
    De Winter, Benedicte
    Van Steenkiste, Christophe
    Francque, Sven
    Vanden Berghe, Tom
    CELL DEATH AND DIFFERENTIATION, 2024, : 1113 - 1126
  • [44] Association between primary hypothyroidism and metabolic dysfunction-associated steatotic liver disease: an updated meta-analysis
    Mantovani, Alessandro
    Csermely, Alessandro
    Bilson, Josh
    Borella, Niccolo
    Enrico, Scoccia
    Pecoraro, Barbara
    Shtembari, Emigela
    Morandin, Riccardo
    Polyzos, Stergios A.
    Valenti, Luca
    Tilg, Herbert
    Byrne, Christopher D.
    Targher, Giovanni
    GUT, 2024, 73 (09) : 1554 - 1561
  • [45] Genetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of the Art Update
    Sookoian, Silvia
    Rotman, Yaron
    Valenti, Luca
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (11) : 2177 - 2187
  • [46] Metabolic dysfunction-associated steatotic liver disease and cancer risk: A cohort study
    Peng, Yu
    Wang, Peng
    Liu, Fubin
    Wang, Xixuan
    Si, Changyu
    Gong, Jianxiao
    Zhou, Huijun
    Gu, Jiale
    Qin, Ailing
    Song, Weijie
    Song, Fangfang
    DIABETES OBESITY & METABOLISM, 2025, 27 (04) : 1940 - 1949
  • [47] Cardiovascular disease and metabolic dysfunction-associated steatotic liver disease: pathophysiology and diagnostic aspects
    Moller, Soren
    Kimer, Nina
    Hove, Jens Dahlgaard
    Barlose, Mads
    Gluud, Lise Lotte
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2025,
  • [48] Natural history of lean and non-lean metabolic dysfunction-associated steatotic liver disease
    Wakabayashi, Shun-Ichi
    Tamaki, Nobuharu
    Kimura, Takefumi
    Umemura, Takeji
    Kurosaki, Masayuki
    Izumi, Namiki
    JOURNAL OF GASTROENTEROLOGY, 2024, 59 (06) : 494 - 503
  • [49] Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease Is Independently Associated With Reduced Renal Function
    Villarroel, Carolina
    Karim, Gres
    Sehmbhi, Mantej
    Debroff, Jake
    Weisberg, Ilan
    Dinani, Amreen
    GASTRO HEP ADVANCES, 2024, 3 (01): : 122 - 127
  • [50] The Predictive Role of miRNAs in Hepatitis B Vaccine Response of Metabolic Dysfunction-Associated Steatotic Liver Disease Patients
    Eskiler, Gamze Guney
    Karabay, Oguz
    Tozlu, Mukaddes
    Aydin, Ayhan
    Hamarat, Kaan Furkan
    Alkurt, Umut
    Ozkan, Asuman Deveci
    Gunduz, Yasemin
    VIRUSES-BASEL, 2024, 16 (11):